Why Do Some Medications Make You Gain Weight, And What Can You Do About It?

Why Medications Cause Weight Gain

Medications produce weight gain through several distinct mechanisms depending on the drug class involved.

Increased appetite. Some medications directly stimulate appetite through effects on hypothalamic hunger regulation, leptin signaling, or other appetite controlling pathways. Patients on these medications experience genuine increased hunger, not a lack of willpower, that drives increased caloric intake.

Fluid retention. Some medications cause the kidneys to retain sodium and water, producing weight gain from fluid accumulation rather than fat. This type of weight gain typically develops more rapidly than fat accumulation and may be accompanied by ankle swelling or a feeling of bloating.

Reduced metabolic rate. Some medications reduce basal metabolic rate, the calories the body burns at rest, through effects on thyroid function, sympathetic nervous system activity, or mitochondrial energy production. Patients eating the same diet they maintained before starting the medication gain weight because their body is burning fewer calories.

Altered glucose and insulin metabolism. Some medications increase insulin levels or insulin resistance, promoting fat storage and reducing the body’s ability to use fat as an energy source.

Sedation reducing physical activity. Medications that cause significant sedation or fatigue reduce the energy available for physical activity, indirectly reducing caloric expenditure.

The Major Drug Classes and Their Weight Effects

Antidepressants, significant concern for several classes

Tricyclic antidepressants, amitriptyline, nortriptyline, imipramine, are among the most consistently weight promoting medications in clinical practice. They stimulate appetite through antihistamine and anticholinergic effects and commonly produce gains of 3 to 5 kilograms or more over the course of treatment.

Among SSRIs, the most widely prescribed antidepressants, paroxetine has the most consistent association with weight gain. Sertraline, escitalopram, and fluoxetine have more modest effects and some patients actually lose weight initially before weight neutral or modest weight gain effects emerge over longer treatment periods.

Mirtazapine, an atypical antidepressant, is strongly associated with weight gain through potent antihistamine activity that stimulates appetite significantly. It is sometimes prescribed specifically to underweight or anorexic patients for this reason.

Bupropion, sold as Wellbutrin for depression and Zyban for smoking cessation, is the antidepressant most consistently associated with weight neutrality or modest weight loss rather than gain. It works through dopamine and norepinephrine pathways that have mild appetite suppressing effects. For patients who have experienced significant weight gain on other antidepressants, bupropion is sometimes considered as an alternative, when clinically appropriate and in the absence of contraindications including seizure disorders and eating disorders.

Antipsychotics, among the most significant weight promoting medications

Atypical antipsychotics, olanzapine, clozapine, quetiapine, risperidone, and aripiprazole, are prescribed for schizophrenia, bipolar disorder, treatment resistant depression, and increasingly as adjunctive therapy for various psychiatric conditions. Several of these medications are among the most potent weight promoting drugs in clinical use.

Olanzapine and clozapine carry the highest weight gain risk in this class, average weight gains of 4 to 5 kilograms over 10 weeks have been documented in clinical trials, with longer term gains substantially higher in some patients. The mechanism involves potent antagonism of histamine H1 receptors, producing significant appetite stimulation, combined with effects on insulin sensitivity that promote fat storage.

Quetiapine has moderate weight gain risk. Aripiprazole and ziprasidone have lower weight gain profiles within the class. For patients on antipsychotics experiencing significant weight gain, a conversation with the prescribing psychiatrist about switching within the class may be worth having, though antipsychotic selection involves clinical considerations beyond weight effects that must be prioritized.

Mood stabilizers, significant concern for several agents

Lithium, used for bipolar disorder, causes weight gain in a significant percentage of patients through mechanisms including increased appetite, fluid retention, and effects on thyroid function. Weight gains of 4 to 10 kilograms over the course of treatment have been documented.

Valproic acid, divalproex sodium, Depakote, is one of the most consistently weight promoting mood stabilizers, with average gains in the range of 5 to 10 kilograms over longer treatment periods. The mechanism includes appetite stimulation, increased insulin levels, and effects on fat metabolism.

Lamotrigine has a significantly more favorable weight profile than lithium or valproate and is sometimes preferred in part for this reason when clinically appropriate.

Corticosteroids, fluid retention plus appetite stimulation

Prednisone, methylprednisolone, and other systemic corticosteroids cause weight gain through multiple mechanisms simultaneously: fluid and sodium retention that produces rapid weight gain from water accumulation, increased appetite through central mechanisms, and insulin resistance that promotes fat storage, particularly in the abdomen, face, and upper back in the characteristic pattern of Cushingoid weight distribution.

Short courses of corticosteroids, five to seven days, produce temporary fluid weight gain that typically resolves within one to two weeks of discontinuation. Long term corticosteroid use produces both fluid weight and true fat accumulation that does not fully reverse on discontinuation.

Diabetes medications, variable effects by class

Insulin therapy is associated with weight gain through several mechanisms including reduced glucosuria as blood sugar control improves, anabolic effects of insulin on muscle and fat tissue, and in some patients hypoglycemia driven compensatory eating.

Sulfonylureas, glipizide, glyburide, glimepiride, stimulate insulin release and are associated with modest weight gain comparable to insulin in some studies.

Thiazolidinediones, pioglitazone, cause both fluid retention and fat redistribution that produces meaningful weight gain in a significant percentage of patients.

In contrast, metformin is weight neutral or associated with modest weight loss in most patients, one of the reasons it remains preferred as first line therapy. GLP 1 receptor agonists, semaglutide, liraglutide, dulaglutide, are associated with significant weight loss and have changed the treatment landscape for both diabetes and obesity management significantly.

SGLT 2 inhibitors, empagliflozin, dapagliflozin, canagliflozin, are associated with modest weight loss through glucosuria and are generally weight favorable among diabetes medications.

Beta blockers, modest but real weight effects

Beta blockers, metoprolol, atenolol, carvedilol, propranolol, are associated with modest weight gain in some patients, primarily through reduced metabolic rate and reduced exercise tolerance from heart rate limitation. The weight effects are generally modest, typically two to three kilograms, but are worth acknowledging in patients who are weight sensitive and who have clinically appropriate alternatives within the antihypertensive medication class.

Among beta blockers carvedilol and nebivolol have somewhat more favorable metabolic profiles than older agents like metoprolol and atenolol, though the differences are modest.

Antihistamines, modest effects with chronic use

First generation antihistamines, diphenhydramine, used chronically for sleep produce weight gain through histamine H1 antagonism that stimulates appetite. This is the same mechanism responsible for the appetite stimulating effect of many antidepressants. Diphenhydramine is not recommended for chronic use in older adults for multiple reasons including cognitive effects, but the weight effect is an additional consideration for any patient using it regularly.

Second generation antihistamines, loratadine, cetirizine, fexofenadine, used daily for seasonal allergies have been associated with modest weight gain in some epidemiological studies, though the clinical significance in individual patients is generally small.

What You Can Do

Document the timeline clearly. If you believe a medication is causing weight gain, document when the medication started and when weight gain began. A clear temporal relationship between medication initiation and weight gain onset is important information for the conversation with your physician.

Bring it up specifically and persistently. Medication induced weight gain is real and worth addressing. If your physician dismisses the concern without exploring whether a weight neutral alternative exists within the same drug class, that dismissal deserves a follow up. You are entitled to a specific answer to the question: ”Is there an alternative medication in this class that has a more favorable weight profile?”

Ask about alternatives within the class. In many drug classes, antidepressants, antipsychotics, diabetes medications, antihypertensives, options exist with meaningfully different weight profiles. Switching from olanzapine to aripiprazole, from paroxetine to bupropion, or from a sulfonylurea to an SGLT 2 inhibitor may produce equivalent clinical benefit with a substantially better weight outcome. These switches require clinical judgment and physician management, but they are often possible.

Do not stop the medication without discussing it with your physician. Medication induced weight gain is frustrating. It is not, in most cases, a reason to stop a medication that is providing genuine clinical benefit without first exploring alternatives with your prescriber. The risks of unmanaged depression, psychosis, diabetes, or cardiovascular disease typically outweigh the risks of medication induced weight gain in isolation.

Address what you can control. Medication induced weight gain does not mean that diet and exercise are irrelevant. The metabolic effects of some medications make weight management harder, they do not make it impossible. Nutritional support, structured physical activity, and behavioral strategies can meaningfully reduce the magnitude of medication induced weight gain even when they cannot eliminate it entirely.

Consider a pharmacist led medication review. A comprehensive review of your complete medication list by a clinical pharmacist can identify which of your current medications carry the highest weight gain risk, whether alternatives with better weight profiles exist, and whether any supplement or nutritional intervention has evidence supporting its use alongside your specific medication regimen.

The Honest Bottom Line

Medication induced weight gain is one of the most common reasons patients stop taking medications that are genuinely helping them, which makes it a clinical safety issue, not just a cosmetic concern. A patient who stops their antipsychotic because of weight gain and experiences a psychiatric relapse has traded one problem for a potentially more serious one.

The correct response to medication induced weight gain is not silent suffering, not unilateral discontinuation, and not accepting a physician dismissal as the final word. It is a specific, documented, persistent conversation about whether alternatives exist, and if they do not, about what strategies can minimize the impact of a side effect that is real, physiological, and worth taking seriously.

This article is for general information only and is not a substitute for personalized medical advice. Before starting or changing any medication, including over the counter products and supplements, talk with your pharmacist or physician about your specific situation.